A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

  • STATUS
    Recruiting
  • End date
    May 22, 2022
  • participants needed
    300
  • sponsor
    Allakos, Inc.
Updated on 4 August 2021
hysterectomy
dysphagia
eosinophil count
eosinophilia
ak002

Summary

This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.

Details
Condition Eosinophilic esophagitis
Treatment Placebo, Antolimab (AK002), lirentelimab (AK002)
Clinical Study IdentifierNCT04322708
SponsorAllakos, Inc.
Last Modified on4 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note